Phio Pharmaceuticals Corp. (PHIO)
$
2
+0.29 (14.50%)
Key metrics
Financial statements
Free cash flow per share
-0.1343
Market cap
8.4 Million
Price to sales ratio
0
Debt to equity
0
Current ratio
10.5795
Income quality
0.8548
Average inventory
0
ROE
-1.0565
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Phio Pharmaceuticals Corp. develops innovative immuno-oncology therapeutics in the United States, focusing on harnessing the immune system to combat cancer. The company offers the INTASYL therapeutic platform, which targets tumor and immune cells through the regulation of immune system genes. In its pipeline, Phio Pharmaceuticals is developing PH-762, which activates immune cells to identify and destroy cancerous cells by lowering the expression of the checkpoint protein PD-1 for immunotherapy in adoptive cell transfer (ACT). Additionally, PH-894 is designed to silence the epigenetic protein BRD4, functioning as an intracellular gene expression regulator to enhance ACT outcomes. Furthermore, PH-804 aims to inhibit the suppressive immune receptor TIGIT, a checkpoint protein found on T cells and natural killer cells, facilitating improved ACT responses. The company incurred an income tax expense of $0.00 indicating its tax obligations, while the total costs and expenses for the company are $0.00 reflecting its overall spending. The gross profit ratio is 0.00 underscoring the efficiency of the company's production and sales operations. The net total of other income and expenses is $237,000.00 reflecting non-core financial activities, and all financial data pertains to the fiscal year 2024. Phio Pharmaceuticals has established collaborations with AgonOx Inc. to advance the clinical development of novel T cell-based cancer immunotherapies. Formerly known as RXi Pharmaceuticals Corporation, the company underwent a name change to Phio Pharmaceuticals Corp. in November 2018 and is headquartered in Marlborough, Massachusetts. With a market capitalization of $9,596,300.00 the company is classified as a small-cap player in the biotechnology industry, contributing significantly to the overall market landscape. The stock is affordable at $2.00 making it suitable for budget-conscious investors. Nevertheless, it has a low average trading volume of 3,205,214.00 indicating lower market activity. The firm belongs to the Healthcare sector, driving innovation and growth within its field. As a key player in the Biotechnology industry, Phio Pharmaceuticals Corp. remains dedicated to advancing therapeutic solutions that enhance patient outcomes and address unmet medical needs in cancer treatment.
Is Phio Pharmaceuticals Corp. (PHIO) a good investment?
Investing in Phio Pharmaceuticals Corp. (PHIO) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C-, with a Bullish outlook. Always conduct your own research before investing.
What is Phio Pharmaceuticals Corp. (PHIO)'s stock forecast?
Analysts predict Phio Pharmaceuticals Corp. stock to fluctuate between $0.97 (low) and $9.79 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Phio Pharmaceuticals Corp.'s market capitalization?
As of 2025-05-29, Phio Pharmaceuticals Corp.'s market cap is $9,596,300, based on 4,798,150 outstanding shares.
How does Phio Pharmaceuticals Corp. compare to competitors like Meta Platforms, Inc. Class A Common Stock?
Compared to Meta Platforms, Inc. Class A Common Stock, Phio Pharmaceuticals Corp. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Phio Pharmaceuticals Corp. (PHIO) stock?
To buy Phio Pharmaceuticals Corp. (PHIO) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for PHIO. Place an order (Market, Limit, etc.).
What is the best time to invest in Phio Pharmaceuticals Corp.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
Has Phio Pharmaceuticals Corp. stock ever split?
Phio Pharmaceuticals Corp.'s last stock split was 1:9 on 2024-07-05.
How did Phio Pharmaceuticals Corp. perform in the last earnings report?
Revenue: $0 | EPS: -$0.91 | Growth: -98.06%.
Where can I find Phio Pharmaceuticals Corp.'s investor relations reports?
Visit https://www.phiopharma.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Phio Pharmaceuticals Corp.?
You can explore historical data from here
What is the all-time high and low for Phio Pharmaceuticals Corp. stock?
All-time high: $470.88 (2021-02-18) | All-time low: $0.97 (2025-04-08).
What are the key trends affecting Phio Pharmaceuticals Corp. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
newsfilecorp.com
Registration Link for Presentation to take place Thursday, May 22, 2025 at 10:00 AM ET Marlborough, Massachusetts--(Newsfile Corp. - May 19, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that Mr.
newsfilecorp.com
Complete Pathologic Response reported in 2 patients in the Third Cohort with cutaneous squamous cell carcinoma, complementing results in prior cohort Phio to present trial results to date at a podium presentation at Society for Investigative Dermatology (SID) Annual Meeting on May 10th Marlborough, Massachusetts--(Newsfile Corp. - May 7, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that a complete pathologic response (100% tumor clearance) has been reported for 2 of 3 patients with cutaneous squamous cell carcinoma (cSCC) treated in the third dose cohort.
newsfilecorp.com
Registration Link for Presentation and live Q&A to take place, Wednesday, May 7, 2025 at 2:00 pm EST Marlborough, Massachusetts--(Newsfile Corp. - May 1, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that Mr.
zacks.com
PHIO and TGS made it to the Zacks Rank #1 (Strong Buy) value stocks list on April 23, 2025.
zacks.com
Phio Pharmaceuticals stock rallies as safety committee gives green light to advance skin cancer candidate to next dose concentration in phase I study.
newsfilecorp.com
-Phio's lead clinical siRNA compound PH-762 demonstrates supportive safety profile in third cohort, permitting escalation in next dose concentration Marlborough, Massachusetts--(Newsfile Corp. - April 9, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® siRNA gene silencing technology to eliminate cancer. Phio announced today that the Safety Monitoring Committee (SMC) recommended dose escalation in Phio's Phase 1b clinical trial (NCT 06014086) for Phio's lead product candidate, PH-762.
newsfilecorp.com
To be presented at 11th Annual Immunotherapy of Cancer (ITOC) Conference in Munich, Germany Marlborough, Massachusetts--(Newsfile Corp. - April 3, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biotechnology company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio today announced that podium presentations will be given on its two lead INTASYL product candidates, PH-762 and PH-894.
newsfilecorp.com
Interim Results from clinical study for cutaneous carcinomas presented at Late-Breaking Research Session Marlborough, Massachusetts--(Newsfile Corp. - March 10, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company developing therapeutics that use its INTASYL® siRNA gene silencing technology designed to make the body's immune cells more effective in killing cancer cells. Phio today announced that a podium presentation addressing its lead product candidate, PH-762, was given in the Academy's Late-Breaking Research session.
newsfilecorp.com
Marlborough, Massachusetts--(Newsfile Corp. - March 5, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company developing therapeutics that use its INTASYL® siRNA gene silencing technology designed to make the body's immune cells more effective in killing cancer cells. Phio announced today that it has fulfilled the required enrollment for safety in its third dose cohort in its Phase 1b dose escalating clinical study for their lead compound PH-762.
newsfilecorp.com
Registration Link for Presentation and live Q&A to take place, Wednesday March 5, 2025 at 12:00 pm EST Marlborough, Massachusetts--(Newsfile Corp. - February 26, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) a clinical-stage biotechnology company developing therapeutics that use its INTASYL® siRNA gene silencing technology designed to make the body's immune cells more effective in killing cancer cells. Phio announced today that Mr.
See all news
